Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bellus Health Inc. - a GSK company
Duration of treatment: 12 months. Patients who complete the Phase III clinical trial will be offered the opportunity to receive Tramiprosate (3APS) in an open-label extension study
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient must have successfully completed the full 78-week duration of the double-blind CL-758007 study.
Male or female (age 50 years and older): Female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal).
Patient must be living in the community with a reliable caregiver. Participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver.
The patient must be presenting a reasonably good nutritional status.
Signed inform consent from the patient or legal representative.
You may not be if
Patients will not be eligible to participate in the study if they meet any of the following criteria:
The patient participates in another drug trial during the study.
The patient with a clinically significant and/or uncontrolled condition or other significant medical disease.
The patient is unable to swallow medication tablets.
